incb099280

INCB099280 is an orally bioavailable, small molecule inhibitor of programmed cell death ligand 1 (PD-L1; also known as CD274), developed as an immune checkpoint inhibitor for the treatment of cancer. By blocking PD-L1, it prevents tumor cells from evading immune detection, thereby enhancing the body’s immune response against cancer cells. The drug is being investigated in multiple clinical trials for advanced solid tumors and specific cancers such as cutaneous squamous cell carcinoma, hepatocellular carcinoma, MSI-H/dMMR tumors, urothelial carcinoma, small-cell lung cancer, and Merkel cell carcinoma. It is administered orally and has shown preliminary efficacy and acceptable safety in early-phase studies[1][2][4][7][8].